Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04353765 · ClinicalTrials.gov registry record
Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors
A clinical trial of Locally Advanced or Metastatic Renal Cell Carcinoma, sponsored by Ipsen.
- Completed
- Registry status
- 247
- Enrollment target
- 1
- Study location
NCT04353765 is a study of Locally Advanced or Metastatic Renal Cell Carcinoma that has completed, run by Ipsen. The registered enrollment target is 247 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04353765, a study of Locally Advanced or Metastatic Renal Cell Carcinoma, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- 247 participants
- Enrollment target
- 1
- Study location
Study Summary
To understand the epidemiology, treatment patterns and outcomes of patients with metastatic Renal Cell Carcinoma (mRCC). Data from mRCC patients who received cabozantinib versus non-cabozantinib Tyrosine Kinase Inhibitor (TKI) (a type of targeted cancer drug) immediately after Check Point Inhibitor (CPI) treatment (a type of immunotherapy that blocks proteins that stop the immune system from attacking the cancer cells) in US community oncology practices will be analyzed.
Conditions Studied
Interventions
- DRUG Cabozantinib monotherapy
- DRUG All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC
Study Locations (1)
Texas
- McKesson Life Sciences - The Woodlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2020-01-30 |
| Est. Completion | 2020-06-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04353765
The ClinicalTrials.gov registry entry for NCT04353765 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced or Metastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Cabozantinib monotherapy is the first listed.
NCT04353765 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04353765 about?
NCT04353765 is a clinical study titled "Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors". To understand the epidemiology, treatment patterns and outcomes of patients with metastatic Renal Cell Carcinoma (mRCC). Data from mRCC patients who received cabozantinib versus non-cabozantinib Tyrosine Kinase Inhibitor (TKI) (a type of targeted cancer drug) immediately after Check Point Inhibitor ...
What is the current status of trial NCT04353765?
This trial is currently completed. The enrollment target is 247 participants. The study started on 2020-01-30. Estimated completion is 2020-06-05.
What conditions does trial NCT04353765 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic Renal Cell Carcinoma.
What interventions are being tested in trial NCT04353765?
The interventions under investigation include: Cabozantinib monotherapy (DRUG), All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC (DRUG).
Who is sponsoring clinical trial NCT04353765?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04353765 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.